References
- Backstrom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta. Neurol. Scand.54, 321–347 (1976).
- Edwards HE, Burnham WM, Mendonca A, Bowlby DA, MacLusky NJ. Steroid hormones affect limbic afterdischarge thresholds and kindling rates in adult female rats. Brain Res.838, 136–150 (1999).
- Reddy DS. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3α-androstanediol and 17β-estradiol. Neuroscience129(1), 195–207 (2004).
- Reddy DS. Anticonvulsant activity of the testosterone-derived neurosteroid 3α-androstanediol. NeuroReport15(3), 515–518 (2004).
- Edwards HE, Burnham WM, MacLusky NJ. Testosterone and its metabolites affect afterdischarge thresholds and the development of amygdala kindled seizures. Brain Res.838, 151–157 (1999).
- Pouliot WA, Handa RJ, Beck SG. Androgen modulates N-methyl-D-aspartate-mediated depolarization in CA1 hippocampal pyramidal cells. Synapse23, 10–19 (1996).
- Frye CA, Rhodes ME, Walf AA, Harney JP. Testosterone reduces pentylenetetrazole-induced ictal activity of wild type mice but not those deficient in Type I 5α-reductase. Brain Res.918, 182–186 (2001).
- Frye CA, Bayon LE. Seizure activity is increased in endocrine states characterized by decline in endogenous levels of the neuroactive steroid 3α,5α-THP. Neuroendocrinology68, 272–280 (1998).
- Smith SS, Gong QH, Hsu F-C, Markowitz RS, French-Mullen JMH, Li X. GABAA receptor α4-subunit suppression prevents withdrawal properties of an endogenous steroid. Nature392, 926–930 (1998).
- Reddy DS, Castaneda DC, O’Malley BW, Rogawski MA. Anticonvulsant activity of progesterone and neurosteroids in progesterone receptor knockout mice. J. Pharmacol. Exp. Ther.310(1), 230–239 (2004).
- Mejias-Aponte CA, Jimenez-Rivera CA, Segarra AC. Sex differences in models of temporal lobe epilepsy: role of testosterone. Brain Res.944, 210–218 (2002).
- Miller WR. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin. Oncol.30(4 Suppl. 14), 3–11 (2003).
- Wickman S, Kajantie E, Dunkel L. Effects of suppression of estrogen action by the P450 aromatase inhibitor letrozole on bone mineral and bone turnover in pubertal boys. . J. Clin. Endocrinol. Metab.88(8), 3785–3793 (2003).
- Leder BZ, Rohrer JL, Rubin SD, Gallo J, Longcope C. Effect of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels. J. Clin. Endocrinol. Metab.89(3), 1174–1180 (2004).
- Herzog AG, Klein P, Jacobs AR. Testosterone versus testosterone and testolactone in treating reproductive and sexual dysfunction in men with epilepsy and hypogonadism. Neurology50, 782–784 (1998).
- Harden C, MacLusky NJ. Aromatase inhibition, testosterone, and seizures. Epilepsy Behavior5, 260–263 (2004).
- Harden CL, Nikolov BG, Labar DL, MacLusky NJ. Aromatase inhibitors as Add-on treatment for men with epilepsy. Neurology62(7 Suppl. 5), 118–199 (2004).
- Bauer J, Blumenthal S, Reuber M, Stoffel-Wagner B. Epilepsy syndrome, focus location, and treatment choice affect testicular function in men with epilepsy. Neurology62(2), 243–246 (2004).